Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilberto Fronza

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Hematological Oncology|August 12, 2022
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective studyGiuseppa De Luca, Giannamaria Cerruti, Sonia Lastraioli, et al.
Pigment Cell & Melanoma Research|November 20, 2015
The CDKN2A/p16(INK) (4a) 5'UTR sequence and translational regulation: impact of novel variants predisposing to melanomaVirginia Andreotti, Alessandra Bisio, Brigitte Bressac-de Paillerets, et al.
Scientific Reports|October 29, 2020
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patientsPaola Monti, Marta Lionetti, Giuseppa De Luca, et al.
Biochimica Et Biophysica Acta. General Subjects|September 20, 2019
SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutationsAna Sara Gomes, Helena Ramos, Sara Gomes, et al.
Expert Opinion on Investigational Drugs|June 20, 2020
TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitorsFortunato Morabito, Massimo Gentile, Paola Monti, et al.
Frontiers in Oncology|August 19, 2021
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic LeukemiaFortunato Morabito, Giovanni Tripepi, Riccardo Moia, et al.
Leukemia|February 22, 2023
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL studyRiccardo Bomben, Francesca Maria Rossi, Filippo Vit, et al.
Blood Advances|July 12, 2022
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cellsSerena Matis, Anna Grazia Recchia, Monica Colombo, et al.
American Journal of Hematology|April 17, 2023
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemiaFortunato Morabito, Giovanni Tripepi, Francesca Romana Mauro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2021
<i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic LeukemiaRiccardo Bomben, Francesca Maria Rossi, Filippo Vit, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Hematological Oncology|August 12, 2022
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective studyGiuseppa De Luca, Giannamaria Cerruti, Sonia Lastraioli, et al.
Pigment Cell & Melanoma Research|November 20, 2015
The CDKN2A/p16(INK) (4a) 5'UTR sequence and translational regulation: impact of novel variants predisposing to melanomaVirginia Andreotti, Alessandra Bisio, Brigitte Bressac-de Paillerets, et al.
Scientific Reports|October 29, 2020
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patientsPaola Monti, Marta Lionetti, Giuseppa De Luca, et al.
Biochimica Et Biophysica Acta. General Subjects|September 20, 2019
SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutationsAna Sara Gomes, Helena Ramos, Sara Gomes, et al.
Expert Opinion on Investigational Drugs|June 20, 2020
TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitorsFortunato Morabito, Massimo Gentile, Paola Monti, et al.
Frontiers in Oncology|August 19, 2021
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic LeukemiaFortunato Morabito, Giovanni Tripepi, Riccardo Moia, et al.
Leukemia|February 22, 2023
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL studyRiccardo Bomben, Francesca Maria Rossi, Filippo Vit, et al.
Blood Advances|July 12, 2022
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cellsSerena Matis, Anna Grazia Recchia, Monica Colombo, et al.
American Journal of Hematology|April 17, 2023
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemiaFortunato Morabito, Giovanni Tripepi, Francesca Romana Mauro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2021
<i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic LeukemiaRiccardo Bomben, Francesca Maria Rossi, Filippo Vit, et al.
Pageof 7